Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01057225 · ClinicalTrials.gov registry record · Phase 1
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01057225: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01057225 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01057225, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells by blocking blood flow to the tumor. Giving combination chemotherapy together with carfilzomib and thalidomide may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of carfilzomib when given together with cyclophosphamide, thalidomide, and dexamethasone in treating patients with newly diagnosed active multiple myeloma.
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG carfilzomib
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2010-03 |
| Est. Completion | 2017-09-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01057225
The ClinicalTrials.gov registry entry for NCT01057225 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT01057225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01057225 about?
NCT01057225 is a clinical study titled "Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma". RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell...
What is the current status of trial NCT01057225?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2010-03. Estimated completion is 2017-09-05.
What interventions are being tested in trial NCT01057225?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), carfilzomib (DRUG), thalidomide (DRUG).
Who is sponsoring clinical trial NCT01057225?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.